Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 624 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Adaptive Biotechnologies Corp. terlibat dalam pengembangan platform obat imun. Perusahaan ini berkantor pusat di Seattle, Washington dan saat ini mempekerjakan 624 karyawan penuh waktu. Perusahaan ini melakukan IPO pada 27 Juni 2019. Perusahaan ini berfokus pada pemanfaatan biologi bawaan dari sistem imun adaptif untuk mengubah diagnosis dan pengobatan penyakit. Platform obat imun mereka mengungkapkan dan menerjemahkan genetika besar dari sistem imun adaptif dengan skala, presisi, dan kecepatan. Perusahaan ini menerapkan platformnya untuk bermitra dengan perusahaan biofarmasi, memberi informasi dalam pengembangan obat, dan mengembangkan diagnosis klinis di dua segmen bisnisnya: Penyakit Residual Minimal (MRD) dan Obat Imun. Bisnis MRD berfokus pada penggunaan uji coba pengurutan generasi berikutnya (NGS) yang sensitif untuk mengukur MRD pada pasien dengan keganasan hematologi. Bisnis MRD mereka terdiri dari tes diagnosis klinis clonoSEQ yang ditawarkan kepada para klinisi. Bisnis IM berfokus pada penemuan dan pengembangan terapi berbasis imun yang transformatif dalam pengobatan pasien dengan kanker dan penyakit autoimun.

Adaptive Biotechnologies

Google

Apple

Microsoft

Amazon

Broadcom

Meta Platforms

Eli Lilly

JPMorgan

Oracle

Exxon Mobil

Johnson & Johnson

ASML

MasterCard

SPDR S&P500 ETF

Palantir

Costco

Bank of America

General Electric

Procter & Gamble

Vanguard Total Stock Market ETF

Toyota

Caterpillar

AstraZeneca

Cisco

Goldman Sachs

Lam Research

Wells Fargo

Merck

Novo Nordisk

Novartis

Raytheon Technologies

Philip Morris

Applied Materials

American Express

Royal Bank of Canada

Intel

Abbott

Salesforce

Shell

T-Mobile

Intuitive Surgical

Disney

Shopify

Invesco QQQ Trust

Blackstone

PepsiCo

Boeing

Charles Schwab

Amgen

QUALCOMM

Texas Instruments

S&P Global

Verizon

Arista Networks

Lowe's

Capital One

Southern Copper

Honeywell

Sony

Pfizer

Unilever

Deere

TotalEnergies

ServiceNow

Adobe

Palo Alto Networks

ConocoPhillips

Medtronic

Progressive

Chubb

CrowdStrike

Sanofi

Vertex Pharmaceuticals

Bristol-Myers Squibb

Comcast

Vanguard Dev Markets ETF

Mercadolibre

Starbucks

Enbridge

Carvana

Agnico Eagle

General Dynamics

Vanguard Value ETF

Robinhood

Moody's

Nike

Northrop Grumman

Vanguard Total Bond Market ETF

Duke Energy

Scotiabank

Barclays

Doordash Inc

Marsh & McLennan

NetEase

Adaptive Biotechnologies Stock

About Adaptive Biotechnologies

Key Statistics

People Also Bought